The FDA released the latest installment in its series of draft biosimilar guidances Tuesday, but it's not the one many drugmakers are anxiously awaiting. The newest guidance discusses the design and use of clinical pharmacology studies. Pharmacokinetic (PK) and pharmacodynamic (PD) data are required as part of the FDA's stepwise approach to demonstrating biosimilarity to the reference drug.